| Literature DB >> 32029492 |
Disa Hansson1, Susanne Strömdahl2,3, Ka Yin Leung4, Tom Britton4.
Abstract
OBJECTIVES: Since 2017, the Public Health Agency of Sweden recommends that pre-exposure prophylaxis (PrEP) for HIV should be offered to high-risk individuals, in particular to men who have sex with men (MSM). The objective of this study is to develop a mathematical model investigating the effect of introducing PrEP to MSM in Sweden.Entities:
Keywords: HIV & AIDS; mathematical models; pre-exposure prophylaxis; sexual networks; transmission dynamics
Year: 2020 PMID: 32029492 PMCID: PMC7045051 DOI: 10.1136/bmjopen-2019-033852
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Estimates of partnership and epidemic parameters
| Parameter | Value | Definition | Source |
|
| |||
| | 271.5 days | Mean duration steady partnership | MSM data |
| | 152.8 days | Mean time being single | MSM data |
| | 12.3 days | Mean time between AI within steady partnership | MSM data |
| | 0.360 | Fraction without a steady partner | MSM data |
| | 0.640 | Fraction with a steady partner | MSM data |
| | 0.337 | Fraction high actives | MSM data |
| | 0.663 | Fraction low actives | MSM data |
|
|
| ||
| | 54.1% | Mean condom use steady partner | MSM data |
| | 62.9% | Mean condom use casual partner | MSM data |
| | Rate for a high active to start taking PrEP | Varied | |
|
| |||
| | 0.25 years | High active on PrEP |
|
| | 1.5–3 years | High active not on PrEP | Varied |
| | 3.5–7 years | Low active |
|
|
|
| ||
|
| |||
| | 10.7 days | High active when single | MSM data |
| | 12.5 days | High active when in partnership | MSM data |
| | 66.5 days | Low active when single | MSM data |
| | 97.9 days | Low active when in partnership | MSM data |
|
|
| ||
|
| |||
| | 14.1 days | High active when single | MSM data |
| | 43.7 days | Low active when single | MSM data |
| | 15.4 days | High active when in partnership | MSM data |
| | 66.4 days | Low active when in partnership | MSM data |
|
| |||
| | 109.3 days | High active when single | MSM data |
| | 169.6 days | Low active when single | MSM data |
| | 136.1 days | High active when in partnership | MSM data |
| | 348.9 days | Low active when in partnership | MSM data |
|
| |||
| 70% | Condom efficiency |
| |
| | 0.24 years | Mean time in acute infection stage |
|
| | 60 years | Sexually active lifespan |
|
|
| |||
| 0.1835 | Acute stage URAI |
| |
| 0.0138 | Chronic stage URAI |
| |
| 1.48% | Overall URAI |
| |
| 0.62% | Overall UIAI |
| |
| 2.39 | Of URAI in comparison to UIAI |
| |
| | 0.1301 | Acute stage combined URAI-UIAI |
|
| | 0.0098 | Chronic stage combined URAI-UIAI |
|
AI, anal intercourse; MSM, men who have sex with men; PrEP, pre-exposure prophylaxis; UIAI, unprotected insertive anal intercourse; URAI, unprotected receptive anal intercourse.
Figure 1(A) Estimated prevalence of HIV (y-axis) for the three mixing assumptions and different mean times to antiretroviral therapy (ART) treatment (x-axis). The presented time to ART treatment is for high active individuals, for low actives it is a factor 2.35 higher. (B) The same estimated prevalence as in (A), but now showing the prevalence separately and including the 95% credibility interval (CRI) for the three mixing assumptions. In one simulation, each partnership parameter (estimated from data) was drawn from its distribution. With that set-up of drawn parameters, we calculated the prevalence. This was repeated 1000 times to obtain the credibility interval.
For the three mixing assumptions, we show the estimated mean time to ART corresponding to a prevalence of 5%. For this prevalence and for each of the three mixing assumptions, we also show the route of transmissions and HIV prevalence for the two respective activity degree groups. The shown values for the time to ART treatment are for high active individuals, the time to ART treatment for low actives is 2.35 times larger. For the allocation of the 5% infected we show the percentage of high actives and low actives, respectively, that are HIV positive
| Overall HIV prevalence of 5% | |||
| Proportionate mixing | Fitted assortativity | Complete assortativity | |
| Time to ART (years) | 1.79 | 1.77 | 1.63 |
| Route of transmission | |||
| Steady partner | 35% | 35% | 32% |
| Casual sex when in partnership | 38% | 39% | 41% |
| Casual sex when single | 26% | 26% | 27% |
| HIV prevalence in the group | |||
| High actives | 9.05% | 9.23% | 10.79% |
| Low actives | 2.94% | 2.85% | 2.06% |
ART, antiretroviral therapy.
Figure 2The effect of introducing pre-exposure prophylaxis (PrEP) to sexually high actives. In (A) the x-axis shows different PrEP coverage levels and the y-axis the corresponding HIV prevalence. The three lines show: the HIV prevalence in the total population (black solid line), the HIV prevalence among high actives (lighter short-dashed line) and the HIV prevalence among low actives (darker long-dashed line). (B) Depicts the effect of PrEP by looking at: (1) solely the reduction of susceptibility and no increased testing rate; and (2) solely the increased testing rate and no reduced susceptibility.